| | | | | Major bleeding events | | Matching characteristics | |
Ischemic stroke | ICH | Other major bleeds | | | Event N = 7,799 | Control N = 33,084 | Event N = 1,276 | Control N = 5,097 | Event N = 14,996 | Control N = 60,058 |
| | Age at AF diagnosis, years | | | | | | | | Mean (SD) | 81.1 (7.6) | 81.1 (7.9) | 79.9 (7.3) | 79.9 (7.6) | 80.0 (7.7) | 79.8 (7.8) | | Age, categorized, n (%) | | | | | | | | 65–69 years | 626 (8.0%) | 2,676 (8.1%) | 119 (9.3%) | 482 (9.5%) | 1,498 (10.0%) | 6,282 (10.5%) | | 70–74 years | 1,058 (13.6%) | 4,569 (13.8%) | 197 (15.4%) | 815 (16.0%) | 2,408 (16.1%) | 9,916 (16.5%) | | 75–79 years | 1,582 (20.3%) | 6,647 (20.1%) | 285 (22.3%) | 1,156 (22.7%) | 3,328 (22.2%) | 13,537 (22.5%) | | 80–84 years | 1,791 (23.0%) | 7,318 (22.1%) | 319 (25.0%) | 1,235 (24.2%) | 3,295 (22.0%) | 12,696 (21.1%) | | ≥85 years | 2,742 (35.2%) | 11,874 (35.9%) | 356 (27.9%) | 1,409 (27.6%) | 4,467 (29.8%) | 17,621 (29.3%) | | Gender, n (%) | | | | | | | | Male | 2,913 (37.4%) | 12,287 (37.1%) | 634 (49.7%) | 2,506 (49.2%) | 6,507 (43.4%) | 25,669 (42.7%) | | Female | 4,886 (62.7%) | 20,797 (62.9%) | 642 (50.3%) | 2,591 (50.8%) | 8,489 (56.6%) | 34,389 (57.3%) | | Race, n (%) | | | | | | | | White | 7,194 (92.2%) | 31,539 (95.3%) | 1,191 (93.3%) | 4,901 (96.2%) | 14,018 (93.5%) | 57,668 (96.0%) | | Black | 445 (5.7%) | 1,012 (3.1%) | 50 (3.9%) | 120 (2.4%) | 678 (4.5%) | 1,628 (2.7%) | | Hispanic | 66 (0.9%) | 202 (0.6%) | 17 (1.3%) | 29 (0.6%) | 126 (0.8%) | 306 (0.5%) | | Other | 85 (1.1%) | 288 (0.9%) | 16 (1.3%) | 44 (0.9%) | 156 (1.0%) | 408 (0.7%) | | Unknown | 9 (0.1%) | 43 (0.1%) | 2 (0.2%) | 3 (0.1%) | 18 (0.1%) | 48 (0.1%) | | US geographic location, n (%) | | | | | | | | Northeast | 1,547 (19.8%) | 6,408 (19.4%) | 251 (19.7%) | 975 (19.1%) | 3,251 (21.7%) | 12,450 (20.7%) | | South | 1,970 (25.3%) | 8,599 (26.0%) | 317 (24.8%) | 1,270 (24.9%) | 4,151 (27.7%) | 16,768 (27.9%) | | Midwest | 3,227 (41.4%) | 14,034 (42.4%) | 525 (41.1%) | 2,160 (42.4%) | 5,818 (38.8%) | 24,257 (40.4%) | | West | 1,051 (13.5%) | 4,043 (12.2%) | 183 (14.3%) | 692 (13.6%) | 1,767 (11.8%) | 6,570 (10.9%) | | Other/unknown | 4 (0.1%) | 3 (0.0%) | 0 (0.0%) | 0 (0.0%) | 9 (0.1%) | 12 (0.0%) | | Year of AF diagnosis, n (%) | | | | | | | | 2000–2003 | 4,919 (63.1%) | 20,082 (60.7%) | 715 (56.0%) | 2,651 (52.0%) | 8,935 (59.6%) | 33,254 (55.4%) | | 2004–2006 | 2,132 (27.3%) | 9,449 (28.6%) | 403 (31.6%) | 1,700 (33.4%) | 4,359 (29.1%) | 18,786 (31.3%) | | 2007–2009 | 748 (9.6%) | 3,553 (10.7%) | 158 (12.4%) | 746 (14.6%) | 1,704 (11.4%) | 8,018 (13.4%) | | Duration of study enrollment, n (%) | | | | | | | | 3–<6 months | 1,571 (20.1%) | 6,604 (20.0%) | 342 (26.8%) | 1,324 (26.0%) | 2,123 (14.2%) | 8,582 (14.3%) | | 6–<12 months | 1,341 (17.2%) | 5,671 (17.1%) | 202 (15.8%) | 839 (16.5%) | 2,455 (16.4%) | 9,838 (16.4%) | | 12–<18 months | 933 (12.0%) | 4,030 (12.2%) | 138 (10.8%) | 570 (11.2%) | 1,812 (12.1%) | 7,345 (12.2%) | | 18–<24 months | 740 (9.5%) | 3,160 (9.6%) | 114 (8.9%) | 468 (9.2%) | 1,576 (10.5%) | 6,354 (10.6%) | | 24–36 months | 3,214 (41.2%) | 13,621 (41.2%) | 480 (37.6%) | 1,896 (37.2%) | 7,030 (46.9%) | 27,939 (46.5%) | | Warfarin use, n (%) | | | | | | | | Yes | 2,568 (32.9%) | 10,087 (30.5%) | 532 (41.7%) | 1,968 (38.6%) | 5,594 (37.3%) | 20,576 (34.3%) | | No | 5,231 (67.1%) | 22,997 (69.5%) | 744 (58.3%) | 3,129 (61.4%) | 9,402 (62.7%) | 39,482 (65.7%) |
|
|
